Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Pharmacol Ther. 2023 Jan 9;242:108344. doi: 10.1016/j.pharmthera.2023.108344

Table 3.

Ongoing or planned clinical trials with selective RET inhibitors Selpercatinib and Pralsetinib.

Drug Name of the trial NCT Number Type of cancer Status FDA approval
Selpercatinib LIBRETTO 001 NCT03157128 Advanced solid tumor, NSCLC, MTC Ongoing (Registration complete) positive
Pralsetinib ARROW NCT03037385 Advanced solid tumor, NSCLC and MTC Ongoing (Registration complete) positive
Selpercatinib LIBRETTO-431 NCT04194944 NSCLC Ongoing –
Pralsetinib AcceleRET-Lung NCT04222972 NSCLC Ongoing –
Selpercatinib LIBRETTO-531 NCT04211337 MTC Ongoing –
Pralsetinib AcceleRET-MTC NCT04760288 MTC Planned –